Please Wait...

Analytical Performance Characteristics of a Novel Immunoassay for Quantification of Neurogranin Truncp75 in Human Cerebrospinal Fluid

E.Chassaing, M.Bodnar-Wachtel, T.Schubert, H.Vanderstichele, E.Stoops, and P.Vergnaud

OBJECTIVES

Despite the fact that the core CSF biomarkers (tau, amyloid) reflect on-going pathology in the brains of subjects with Alzheimer’s Disease (AD), new biomarkers are needed to monitor other hallmarks, such as synaptic degeneration. This study documents the analytical performance characteristics of a novel ELISA, targeting P75 truncated Neurogranin, which has been shown to be the most abundant Neurogranin isoform in CSF.

METHODS

After having performed familiarization runs and adaptation of the test procedures to the needs of a service provider, the assay was challenged internally for its analytical performance characteristics (eg, precision, parallelism, spike-recovery, working range, sample stability) by using commercially available CSF samples (n=32).

RESULTS

The new assay format specifically quantifies Neurogranin truncated at position 75. Full-length Neurogranin is not detected. Neurogranin is quantified in the absence of matrix interference (parallelism 101% ± 8%; dilution range: neat – 1/16). Spike/recovery testing revealed good recovery rates (100% ± 8%). The precision resulted in intra- and inter-assay variability (%CV) below 7% and 13%, respectively. The working range is confirmed between 50 pg/mL (Lower Limit of Quantitation) to 1300 pg/mL (Upper Limit of Quantitation). CSF stability at +4°C is acceptable, but storage at room temperature should not exceed 6 hours; consecutive freezing/thawing of CSF up to 4 cycles did not affect Neurogranin concentrations. The assay format is also applicable to EDTA-plasma samples.

CONCLUSIONS

The newly developed Neurogranin TruncP75 colorimetric ELISA assay meets all internal acceptance criteria for clinical trial sample testing and represents an additional tool for patient management.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/1917MtlAsA
Bioclinica (Yesterday)
Thinking of building a study in-house? Here are the 5 things you should think about before starting a DIY study bui… https://t.co/xzZWQOm49S
Bioclinica (6 days ago)
Integration of #eTMF and #CTMS eliminates redundancies, improves workflows & enables greater study control. Join th… https://t.co/Hoqf18zcPF
Bioclinica (1 week ago)
Your #IRT should not be the limiting factor during study start-up. The core features of Bioclinica's IRT agile plat… https://t.co/kitdsWvJ2S
Bioclinica (2 weeks ago)
Presenting Bioclinica CTMS: a rapid startup #CTMS that takes 2 weeks to implement, rather than months. Bioclinica C… https://t.co/tclYFoJx2z
Bioclinica (2 weeks ago)
Improve doc & study mgmt. across all studies by integrating #eTMF & #CTMS. In this webinar, Bioclinica &… https://t.co/UyoQyJVDah
Bioclinica (3 weeks ago)